A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Key-Who May Qualify: - ≥18 years and ≤75 years of age at time of willing to sign a consent form - Participants with histologically and/or cytologically confirmed relapsed or refractory CD19-positive B-cell non-Hodgkin lymphoma - With at least one of evaluable/measurable target lesions per Lugano 2014 criteria - Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 - Life expectancy of ≥3 months - Sufficient organ function Key-Who Should NOT Join This Trial: - Central nervous system lymphoma - Previously undergone allogeneic hematopoietic stem cell transplantation or other organ transplants - Any other prior malignancy active within the previous 5 years, except for skin basal cell cancer that has been cured, or carcinoma in situ of the cervix - History of active autoimmune conditions (where your immune system attacks your own body)s - History of interstitial lung disease, tuberculosis, or other diseases that affect pulmonary function in the past or currently - Uncontrolled disease, including but not limited to uncontrolled diabetes, hypertension, active infections, active peptic ulcers, thromboembolic disease requiring anticoagulation, etc. - Severe cardiovascular diseases - History of severe allergies to protein-based drugs or any component of the study drug Always talk to your doctor about whether this trial is right for you.